sorafenib + pembrolizumab

sorafenib + pembrolizumab is a combination regimen of two pharmaceuticals used primarily in the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib is an oral small molecule multikinase inhibitor that targets tumor cell proliferation and angiogenesis, while pembrolizumab is a monoclonal antibody that acts as an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). The combination leverages the targeted anti-tumor effects of sorafenib with the immune-activating effects of pembrolizumab to potentially improve clinical outcomes, including progression-free survival and overall survival, in advanced HCC, particularly after other treatment modalities such as transcatheter arterial chemoembolization (TACE). Early clinical studies and retrospective analyses suggest enhanced efficacy in disease control with manageable safety profiles compared to monotherapies, but this specific combination is primarily under clinical investigation and not formally FDA approved as a fixed combination product[1][6][7].